甲磺酸伊马替尼联合VDLD化疗方案治疗急性淋巴细胞白血病患儿的疗效及对T细胞免疫功能的影响

目的探讨甲磺酸伊马替尼联合VDLD化疗方案治疗急性淋巴细胞白血病患儿的疗效及对T细胞免疫功能的影响。方法将74例急性淋巴细胞白血病患儿按照随机数字表法均分为2组,对照组37例采用VDLD化疗方案治疗,观察组37例采用甲磺酸伊马替尼联合VDLD化疗方案治疗。比较2组的近期疗效、血常规及凝血指标、T细胞免疫功能变化及不良反应发生情况。结果观察组近期总有效率为91.9%,显著高于对照组的73.0%(P<0.05)。治疗前2组血常规及凝血指标差异常率比较差异均无统计学意义(P>0.05),治疗后观察组患儿血常规中血红蛋白、白细胞计数、红细胞计数、血小板计数异常率显著低于对照组(P<0.05),凝血指标中纤维蛋白原异常率显著低于对照组(P<0.05)。治疗前2组CD3+、CD4+、CD4+/CD8+比较差异无统计学意义(P>0.05),治疗后观察组患儿以上各项水平显著高于对照组(P<0.05)。2组不良反应发生率比较差异均无统计学意义(P>0.05)。结论甲磺酸伊马替尼联合VDLD化疗方案治疗急性淋巴细胞白血病患儿的近期疗效满意,能够显著改善患儿的血常规及凝血指标,提高免疫功能,并且用药安全性可靠。

Curative Effect of Imatinib Mesylate combined with VDLD Chemotherapy Regimen in the Treatment of Children with Acute Lymphoblastic Leukemia and Its Influence on T Cell Immune Function

Objective To investigate the curative effect of Imatinib mesylate combined with VDLD chemotherapy regimen in the treatment of children with acute lymphoblastic leukemia and its influence on T cell immune function.Methods 74 patients with acute lymphoblastic leukemia diagnosed and treated were divided into the 2 groups according to the random number table method,63 patients in the control group were treated with VDLD chemotherapy regimen and 63 patients in the observation group were treated with Imatinib mesylate combined with VDLD chemotherapy regimen.The short-term efficacy,blood routine and coagulation indexes,T cell immune function changes and adverse reactions of the 2 groups were compared.Results The total effective rate of the observation group in the near future is 91.9%,it is significantly higher than 73.0%of the control group(P<0.05).There was no significant difference in the abnormal rate of blood routine and coagulation index between two groups before treatment(P>0.05),the abnormal rate of hemoglobin,white blood cell count,red blood cell count and platelet count in the blood routine of the observation group after treatment were significantly lower than those of the control group(P<0.05),the abnormal rate of plasma fibrinogen in the coagulation index was significantly lower than that in the control group(P<0.05).There was no statistically significant difference in CD3+,CD4+,CD4+/CD8+between the 2 groups before treatment(P>0.05),after treatment,the above items in the observation group were significantly higher than those of the control group(P<0.05).The incidence of adverse reactions in the observation group and control group were compared,the difference was not statistically significant(P>0.05).Conclusion Imatinib mesylate combined with VDLD chemotherapy regimen in the treatment of children with acute lymphoblastic leukemia has satisfactory short-term effects,it can significantly improve the blood routine and coagulation indexes of children,improve immune function,and has reliable drug safety.